Orion Oyj (ORINY) To Go Ex-Dividend on April 7th

Orion Oyj (OTCMKTS:ORINY) announced a dividend on Monday, March 17th, NASDAQ Dividends reports. Stockholders of record on Monday, April 7th will be paid a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date of this dividend is Monday, April 7th. This is a 86.2% increase from Orion Oyj’s previous dividend of $0.24.

Orion Oyj Price Performance

ORINY stock opened at $31.10 on Friday. The firm has a market cap of $8.78 billion, a P/E ratio of 24.68 and a beta of 0.25. The firm’s fifty day moving average is $28.41 and its 200 day moving average is $25.83. Orion Oyj has a 52 week low of $17.50 and a 52 week high of $31.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42.

Orion Oyj (OTCMKTS:ORINY) last issued its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $463.41 million during the quarter. Research analysts predict that Orion Oyj will post 1.18 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.